Abstract | BACKGROUND: METHODS: We analyzed data from the Taiwan National Health Insurance Research Database between March 1st, 2009 and December 31st, 2011. A total of 1025 AMI patients with diabetes with chronic kidney disease were selected as the study cohort. The study evaluated the cardiovascular safety and efficacy of sitagliptin by comparing 205 subjects (20%) who use sitagliptin to 820 matched subjects (80%) who do not. The primary outcomes included myocardial infarction, ischemic stroke or cardiovascular death. RESULTS: CONCLUSIONS:
|
Authors | Dong-Yi Chen, Szu-Heng Wang, Chun-Tai Mao, Ming-Lung Tsai, Yu-Sheng Lin, Chung-Chuan Chou, Ming-Shien Wen, Chun-Chieh Wang, I-Chang Hsieh, Kuo-Chun Hung, Tien-Hsing Chen |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 181
Pg. 200-6
(Feb 15 2015)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 25528312
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
|
Topics |
- Aged
- Cohort Studies
- Diabetes Mellitus, Type 2
(diagnosis, drug therapy, epidemiology)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(diagnosis, drug therapy, epidemiology)
- Patient Discharge
(trends)
- Population Surveillance
- Renal Insufficiency, Chronic
(diagnosis, drug therapy, epidemiology)
- Sitagliptin Phosphate
(therapeutic use)
- Taiwan
(epidemiology)
- Treatment Outcome
|